Prevention of cervical cancer through papillomavirus vaccination (Q35620080)

9 August 2017

1 reference

title

Prevention of cervical cancer through papillomavirus vaccination (English)

1 reference

9 August 2017

main subject

cervix uterine cancer

1 reference

1 reference

Ian H Frazer

1

1 reference

9 August 2017

publication date

1 January 2004

1 reference

Nature Reviews Immunology

9 August 2017

published in

1 reference

9 August 2017

volume

4

1 reference

9 August 2017

issue

1

1 reference

9 August 2017

page(s)

46-54

1 reference

A controlled trial of a human papillomavirus type 16 vaccine

9 August 2017

cites work

1 reference

The causal relation between human papillomavirus and cervical cancer

31 March 2020

1 reference

Hepatitis B vaccination and hepatocellular carcinoma rates in boys and girls

31 March 2020

1 reference

Papillomavirus infections and human genital cancer

31 March 2020

1 reference

Immortalization of human cells and their malignant conversion by high risk human papillomavirus genotypes

31 March 2020

1 reference

Epidemiologic classification of human papillomavirus types associated with cervical cancer

31 March 2020

1 reference

Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia

31 March 2020

1 reference

A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine

31 March 2020

1 reference

Immunology of papillomavirus infection.

31 March 2020

1 reference

Immune evasion in human papillomavirus-associated cervical cancer

31 March 2020

1 reference

Depletion of Langerhans cells in human papillomavirus type 16-infected skin is associated with E6-mediated down regulation of E-cadherin

31 March 2020

1 reference

Subpopulations of Langerhans' cells in cervical neoplasia

31 March 2020

1 reference

Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity

31 March 2020

1 reference

The human papillomavirus E7 oncoprotein abrogates signaling mediated by interferon-alpha.

31 March 2020

1 reference

Inactivation of interferon regulatory factor-1 tumor suppressor protein by HPV E7 oncoprotein. Implication for the E7-mediated immune evasion mechanism in cervical carcinogenesis

31 March 2020

1 reference

Papillomavirus type 16 oncogenes downregulate expression of interferon-responsive genes and upregulate proliferation-associated and NF-kappaB-responsive genes in cervical keratinocytes

31 March 2020

1 reference

Animal models of papillomavirus pathogenesis

31 March 2020

1 reference

Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection

31 March 2020

1 reference

Antibodies against the human papillomavirus type 16 early proteins in human sera: correlation of anti-E7 reactivity with cervical cancer

31 March 2020

1 reference

Effective vaccination against papilloma development by immunization with L1 or L2 structural protein of cottontail rabbit papillomavirus

31 March 2020

1 reference

Spontaneously regressing oral papillomas induce systemic antibodies that neutralize canine oral papillomavirus

31 March 2020

1 reference

Regression of canine oral papillomas is associated with infiltration of CD4+ and CD8+ lymphocytes

31 March 2020

1 reference

Enhancement of the innate and cellular immune response in patients with genital warts treated with topical imiquimod cream 5%

31 March 2020

1 reference

Spontaneous regression of CIN and delayed-type hypersensitivity to HPV-16 oncoprotein E7.

31 March 2020

1 reference

Specific inactivation of inhibitory sequences in the 5' end of the human papillomavirus type 16 L1 open reading frame results in production of high levels of L1 protein in human epithelial cells

31 March 2020

1 reference

In vitro synthesis of oncogenic human papillomaviruses requires episomal genomes for differentiation-dependent late expression

31 March 2020

1 reference

Replication of bovine papillomavirus type 1 (BPV-1) DNA in Saccharomyces cerevisiae following infection with BPV-1 virions.

31 March 2020

1 reference

Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles.

31 March 2020

1 reference

Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic

31 March 2020

1 reference

Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16

31 March 2020

1 reference

A formalin-inactivated vaccine protects against mucosal papillomavirus infection: a canine model

31 March 2020

1 reference

Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles

31 March 2020

1 reference

Immunological analyses of human papillomavirus capsids

31 March 2020

1 reference

A fresh look at tumor immunosurveillance and immunotherapy.

31 March 2020

1 reference

Life cycle heterogeneity in animal models of human papillomavirus-associated disease

31 March 2020

1 reference

Linkage of regression and malignant conversion of rabbit viral papillomas to MHC class II genes

31 March 2020

1 reference

Human leukocyte antigen class I and II alleles and risk of cervical neoplasia: results from a population-based study in Costa Rica.

31 March 2020

1 reference

DNA vaccination prevents and/or delays carcinoma development of papillomavirus-induced skin papillomas on rabbits

31 March 2020

1 reference

Progress in prophylactic and therapeutic vaccines for human papillomavirus infection

31 March 2020

1 reference

Gene gun-mediated DNA vaccination induces antitumor immunity against human papillomavirus type 16 E7-expressing murine tumor metastases in the liver and lungs

31 March 2020

1 reference

Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors

31 March 2020

1 reference

Antigen-specific immunotherapy for murine lung metastatic tumors expressing human papillomavirus type 16 E7 oncoprotein

31 March 2020

1 reference

Regression of established human papillomavirus type 16 (HPV-16) immortalized tumors in vivo by vaccinia viruses expressing different forms of HPV-16 E7 correlates with enhanced CD8(+) T-cell responses that home to the tumor site

31 March 2020

1 reference

Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors im

31 March 2020

1 reference

Therapeutic potential of protein and adjuvant vaccinations on tumour growth

31 March 2020

1 reference

Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides

31 March 2020

1 reference

Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guérin (BCG) hsp65 and HPV16 E7.

31 March 2020

1 reference

Presentation of the HPV16E7 protein by skin grafts is insufficient to allow graft rejection in an E7-primed animal

31 March 2020

1 reference

Induction of T-cell-mediated skin disease specific for antigen transgenically expressed in keratinocytes

31 March 2020

1 reference

Tolerance or immunity to a tumor antigen expressed in somatic cells can be determined by systemic proinflammatory signals at the time of first antigen exposure

31 March 2020

1 reference

Interferon-gamma enhances cytotoxic T lymphocyte recognition of endogenous peptide in keratinocytes without lowering the requirement for surface peptide

31 March 2020

1 reference

Multiple mechanisms underlie HLA dysregulation in cervical cancer

31 March 2020

1 reference

Antigen processing defects in cervical carcinomas limit the presentation of a CTL epitope from human papillomavirus 16 E6.

31 March 2020

1 reference

IL-10 Mediates Suppression of the CD8 T Cell IFN-γ Response to a Novel Viral Epitope in a Primed Host

31 March 2020

1 reference

Loss of MHC class-I expression in cervical carcinomas

31 March 2020

1 reference

Mutations in TAP genes are common in cervical carcinomas

31 March 2020

1 reference

Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine

31 March 2020

1 reference

Activity of HspE7, a novel immunotherapy, in patients with anogenital warts

31 March 2020

1 reference

Immunotherapy of human cervical high-grade cervical intraepithelial neoplasia with microparticle-delivered human papillomavirus 16 E7 plasmid DNA.

31 March 2020

1 reference

A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer.

31 March 2020

1 reference

Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial

31 March 2020

1 reference

HPV6b virus like particles are potent immunogens without adjuvant in man.

31 March 2020

1 reference

Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients

31 March 2020

1 reference

31 March 2020

Identifiers

DOI

10.1038/NRI1260

1 reference

Dimensions Publication ID

9 August 2017

1041769980

0 references

1 reference